|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, knockdown of Six1 significantly prolonged the survival of MLL-AF9-induced AML mice with reduced peripheral infiltration and tumor burden.
|
31050834 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Null mutations of Mll1 in tumor mice and in xenotransplanted human head and neck tumors resulted in loss of self-renewal of tumor-propagating cells and in block of tumor formation but did not alter normal tissue homeostasis.
|
30625324 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Set1/MLL complexes are the main histone H3K4 methyltransferases and are crucial regulators of tumor pathogenesis.
|
31564898 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two different mutational analysis assays of a representative tumor area were performed: first, a singleplex PCR assay for evaluation of the TERT promoter region (TERTSeqS) and second, a multiplex PCR assay using primers designed to amplify regions of interest of 10 (FGFR3, PIK3CA, TP53, HRAS, KRAS, ERBB2, CDKN2A, MET, MLL, and VHL) genes (UroSeqS).
|
31028363 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Trx1/CD30 controls the redox immune homeostasis, and an imbalance in the relationship between the Trx1/RTrx1 and sCD30 levels is linked to the onset and progression of tumor.
|
30788039 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of PHF20L1 weakened the tumor initiation ability of PA-1 cells while ablation of MLL1 promoted the growth of tumors.
|
30089852 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, loss of Baf200 in a mouse model of MLL-AF9-driven leukemogenesis accelerates the tumor burden and shortens the host survival.
|
29482581 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
OICR-9429 treatment was particularly toxic to SW620 and T84 colon cancer cells, two cell lines without mutations in WDR5 and KMT2/MLL proteins suggesting COMPASS complex inhibition may be particularly effective in tumors lacking KMT2 mutations.
|
29925347 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, inhibition of the core BER factor Apurinic-apyrimidinic endonuclease 1 protects against MLLbcr cleavage in tumour and human cord blood-derived haematopoietic stem/progenitor cells, harbouring the cells of origin of leukaemia.
|
28626219 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Delivery of DATS also resulted in decreased expression of Trx-1 as the direct target, as well as expression of NF-κB and MMP2/9 in primary tumor and lung tissue.
|
30396169 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APOBEC-high tumors are more likely to have mutations in DNA damage response genes (<i>TP53, ATR, BRCA2</i>) and chromatin regulatory genes (<i>ARID1A, MLL, MLL3</i>), while APOBEC-low tumors are more likely to have mutations in <i>FGFR3</i> and <i>KRAS</i>.
|
29435122 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A critical dependency of these tumors on the MLL1-menin interaction presents a potentially novel therapeutic target.
|
27888797 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
|
28500307 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of KMT2A knockdown in promoting tumor growth was further confirmed <i>in vivo</i> by transplanting U-87 MG cells into the brains of zebrafish larvae.
|
28968975 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Array comparative genomic hybridization showed two types of duplication: bigger than 50 megabase pairs (Mbp) and smaller than 20 Mbp, which were associated with bulky tumor larger than 20 cm and amplification of the 11q23.3 region, including KMT2A.
|
29272887 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data demonstrate that MLL1 inhibition may be a powerful and effective strategy for inducing cancerous growth arrest through the direct epigenetic regulation of proliferation-promoting genes and the avoidance of deleterious OIS- or TIS-related tumor secretomes, which can promote both drug resistance and tumor progression.
|
26833731 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results demonstrate that Dnmt3b plays a tumor suppressive role in MLL-AF9 AML progression, thereby providing new insights into the roles of DNA methylation in leukemia development.
|
27133822 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Collectively, our data reveal a previously unappreciated signaling pathway involving the MLL-fusion/MYC⊣miR-26a⊣TET1 signaling circuit, in which miR-26a functions as an essential tumor-suppressor mediator and its transcriptional repression is required for the overexpression and oncogenic function of TET1 in MLL-rearranged AML.
|
26791235 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Focusing on epigenetic regulators, we identified WDR5, a core member of the COMPASS histone H3 Lys4 (H3K4) MLL (1-4) methyltransferase complex, as a top tumor maintenance hit required across multiple human and mouse tumors.
|
27320920 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we report a series of 21 patients with myeloid neoplasms associated with MLL gene amplification from 1 institution.
|
25387813 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data also showed upregulation of tumor markers Trx-1 and Ref-1 in rats treated with aniline.
|
26192324 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Furthermore, at concentrations of 5-10nM clofarabine induced demethylation of the promoter region of the tumour suppressor gene FHIT (Fragile Histidine Triad), a gene typically hypermethylated in MLL-rearranged ALL.
|
26188848 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MLL3 was significantly downregulated in tumor samples compared to their normal counterparts, and all MLL genes showed decreased expression in advanced tumors compared to tumors in the initial stage.
|
25633166 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast to the poor clinical outcomes of patients with acute leukemias and myeloid neoplasms associated with KMT2A translocations, patients with B-cell non-Hodgkin lymphomas, exhibiting similar translocations, appear to respond well to immunochemotherapy.
|
25131304 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report two very unusual cases of myeloid neoplasms with homozygous inv(11)(q21q23) and biallelic MLL rearrangement.
|
25031740 |
2014 |